Cite
Canda T, Yavuz E, Özdemir N, et al. Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. Eur J Breast Health. 2018;14(3):160-165doi: 10.5152/ejbh.2018.3961.
Canda, T., Yavuz, E., Özdemir, N., İlvan, S., Dizbay, S. S., Durak, M. G., Tuzlalı, S., Zekioğlu, O., Demir, A., Onur, H., Üstündağ, K., & Göktaş, B. (2018). Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. European journal of breast health, 14(3), 160-165. https://doi.org/10.5152/ejbh.2018.3961
Canda, Tülay, et al. "Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study." European journal of breast health vol. 14,3 (2018): 160-165. doi: https://doi.org/10.5152/ejbh.2018.3961
Canda T, Yavuz E, Özdemir N, İlvan S, Dizbay SS, Durak MG, Tuzlalı S, Zekioğlu O, Demir A, Onur H, Üstündağ K, Göktaş B. Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. Eur J Breast Health. 2018 Jul 01;14(3):160-165. doi: 10.5152/ejbh.2018.3961. eCollection 2018 Jul. PMID: 30123882; PMCID: PMC6092158.
Copy
Download .nbib